daraxonrasib trials for NSCLC

All daraxonrasib trials · All NSCLC trials

Phase breakdown

Recruiting trials studying daraxonrasib for NSCLC

• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
  NCT06881784 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 153 locations
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
  NCT07397338 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations

Common questions

How many trials study daraxonrasib for NSCLC?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.